Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3323-3331

  File Jr , T M ^a   Lode, H ^b   Kurz, H ^c   Kozak, R ^d   Xie, H ^d   Berkowitz, E ^d  

^a SUMMA HEALTH SYSTEM   (United States)

^b Hospital Zehlendorf   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CANDIDIASIS; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENITAL TRACT INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NONHUMAN; POPULATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SIDE EFFECT; SPUTUM ANALYSIS; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; TABLET FORMULATION; THORAX RADIOGRAPHY; VOMITING;

ADOLESCENT; ADULT; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CHEMISTRY, PHARMACEUTICAL; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; SPUTUM; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 4344587733     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3323-3331.2004     Document Type: Article

References (22)

1. Ball, P., F. Baquero, O. Cars, T. File, J. Garau, K. Klugman, D. E. Low, E. Rubinstein, and R. Wise. 2002. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother. 49:31-40.
2. Benninger, M. S. 2003. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia. Expert Opin. Pharmacother. 4:1839-1846.
3. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
4. Craig, W. A. 2001. Introduction-have we reached the point of no return? The hidden impact of antimicrobial resistance in respiratory tract infection. Resp. Med. 9S(Suppl. A):S2-S4.
5. Dagan, R., K. P. Klugman, W. A. Craig, and F. Bacquero. 2001. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 47:129-140.
6. Dagan, R., E. Leibovitz, D. Greenberg, P. Yagupsky, D. M. Fliss, and E. Leiberman. 1998. Early eradication of pathogens from middle-ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr. Infect. Dis. J. 17:776-782.
7. Feikin, D. R., A. Schuchat, M. Kolczak, N. L. Barrett, L. H. Harrison, L. Lefkowitz, A. McGeer, M. M. Farley, D. J. Vugia, C. Lexau, K. R. Stefonek, J. E. Patterson, and J. H. Jorgensen. 2,000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90:223-229.
8. File, T. M., Jr. 2002. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant S. pneumoniae. Clin. Infect. Dis. 34(Suppl. 1):S17-S26.
9. File, T. M., Jr. 2003. Community-acquired pneumonia. Lancet 362:1991-2001.
10. File, T. M., M. R. Jacobs, M. D. Poole, and B. Wynne. 2002. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. Int. J. Antimicrob. Agents. 20:235-247.
11. Finch, R. G., and D. E. Low. 2002. A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections. Clin. Microb. Infect. 8(Suppl. 2):69-91.
12. Fine, M. J., M. A. Smith, C. A. Carson, S. S. Mutha, S. S. Sankey, L. A. Weissfeld, and W. N. Kapoor. 1996. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 275:134-141.
13. Garau, J., M. Twynholm, and E. Garcia-Mendez. 2002. Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2,000/125 mg b.d. versus amoxicillin/clavulanate 875/125 mg t.d.s. in community-acquired pneumonia (CAP). Clin. Microbiol. Infect. 8(Suppl. 1):322.
14. Garau, J. 2004. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae. Clin. Microbiol. Infect. 10(Suppl. 2):28-35.
15. Jacobs, M. R., D. Felmingham, P. C. Appelbaum, R. N. Gruneberg and the Alexander project group. 2003. The Alexander project 1998-2,000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246.
16. Kaye, C. M., A. Alien, S. Perry, M. McDonagh, M. Davy, K. Storm, N. Bird, and O. Dewit. 2001. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin. Ther. 23:578-584.
17. Mandell, L. A., J. G. Bartlett, S. F. Dowell, T. M. File, D. M. Musher, and C. Whitney. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37:1405-1433.
18. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing, 12th informational supplement. Document M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. Niederman, M. S., L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Brougbton, G. D. Campbell, N. Dean, T. File, M. J. Fine, P. A. Gross, F. Martinez, T. J. Marrie, J. F. Plouffe, J. Ramirez, G. A. Sarosi, A. Torres, R. Wilson, and V. L. Yu. 2001. American Thoracic Society guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163:1730-1754.
20. Petitpretz, P., C. Chidiac, F. Soriano, J. Garau, K. Stevenson, and E. Rouffiac. 2002. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin/clavulanate 2,000/125 mg, twice daily, versus oral amoxycillin/clavulanate 1,000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int. J. Antimicrob. Agents 20:119-129.
21. White, A. R., C. Kaye, J. Poupard, R. Pypstra, G. Woodnutt, and B. Wynne. 2004. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53(Suppl. S1):i3-i20.
22. Woodnutt, G., and V. Berry. 1999. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:29-34.